⌘K
Loading ticker…
As of 2026-08-24, Intensity Therapeutics, Inc. Common stock (INTS) has a 3-month relative strength percentile of 50 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 41. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.1%, relative volume 0.87×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
INTS appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $99K notional.
Held by 1 ETFs · $99K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $99K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | INTS Jan avg: -9.30% median: -10.87% win: 33% σ: 34.11% n: 3 2023-07-03 → 2026-07-31 | INTS Feb avg: -11.70% median: -16.19% win: 33% σ: 15.82% n: 3 2023-07-03 → 2026-07-31 | INTS Mar avg: 0.50% median: -15.81% win: 33% σ: 34.88% n: 3 2023-07-03 → 2026-07-31 | INTS Apr avg: -35.51% median: -25.00% win: 0% σ: 30.75% n: 3 2023-07-03 → 2026-07-31 | INTS May avg: -2.50% median: -15.74% win: 33% σ: 25.98% n: 3 2023-07-03 → 2026-07-31 | INTS Jun avg: -14.47% median: -6.61% win: 0% σ: 18.31% n: 3 2023-07-03 → 2026-07-31 | INTS Jul avg: -3.45% median: -2.63% win: 25% σ: 4.73% n: 4 2023-07-03 → 2026-07-31 | INTS Aug avg: -2.48% median: 0.87% win: 67% σ: 6.64% n: 3 2023-07-03 → 2026-07-31 (current) | INTS Sep avg: -19.11% median: -13.94% win: 0% σ: 10.51% n: 3 2023-07-03 → 2026-07-31 | INTS Oct avg: 54.09% median: -14.92% win: 33% σ: 127.19% n: 3 2023-07-03 → 2026-07-31 | INTS Nov avg: -24.80% median: -19.13% win: 0% σ: 18.34% n: 3 2023-07-03 → 2026-07-31 | INTS Dec avg: 70.87% median: 2.73% win: 67% σ: 156.35% n: 3 2023-07-03 → 2026-07-31 |